Dannielle Appelhans

2021

In 2021, Dannielle Appelhans earned a total compensation of $3.7M as Chief Operating Officer at Rubius Therapeutics.

Compensation breakdown

Bonus$130,000
Non-Equity Incentive Plan$76,870
Option Awards$2,185,155
Salary$177,404
Stock Awards$1,086,000
Other$38,706
Total$3,694,135

Appelhans received $2.2M in option awards, accounting for 59% of the total pay in 2021.

Appelhans also received $130K in bonus, $76.9K in non-equity incentive plan, $177.4K in salary, $1.1M in stock awards and $38.7K in other compensation.

Rankings

In 2021, Dannielle Appelhans' compensation ranked 3,615th out of 12,415 executives tracked by ExecPay. In other words, Appelhans earned more than 70.9% of executives.

ClassificationRankingPercentile
All
3,615
out of 12,415
71st
Division
Manufacturing
1,472
out of 5,501
73rd
Major group
Chemicals And Allied Products
599
out of 2,371
75th
Industry group
Drugs
533
out of 2,092
75th
Industry
Biological Products, Except Diagnostic Substances
140
out of 449
69th
Source: SEC filing on March 30, 2022.

Appelhans' colleagues

We found four more compensation records of executives who worked with Dannielle Appelhans at Rubius Therapeutics in 2021.

2021

Pablo Cagnoni

Rubius Therapeutics

Chief Executive Officer

2021

Maiken Keson-Brookes

Rubius Therapeutics

Chief Legal Officer

2021

Laurence Turka

Rubius Therapeutics

Chief Scientific Officer

2021

Jose Carmona

Rubius Therapeutics

Chief Financial Officer

News

In-depth

You may also like